Program
Drugs, Investigational
Also written as “Investigational drug”, “Investigational new drug, company code: BGG492” and “TimoD implant”.
Its studies are mostly in Keratosis, Actinic · Glaucoma · Burns · Glaucoma, Open-Angle · Nervous System Diseases, led by 7 companies.
Drug pageDrugs, Investigational: every studyMany companies study it; this page follows only the 10 they lead. All 14 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| EyeD Pharmaits history only | 21 open or running | phase 2since Jun 17, 2025 | Mar 13, 2024 | Jan 2027phase 2 · NCT07036510 |
| Novartisits history only | 20 open or running | phase 2since Apr 23, 2009 | Apr 23, 2009 | none ahead |
| Pfizerits history only | 20 open or running | phase 2since May 2, 2002 | May 2, 2002 | none ahead |
| Bristol-Myers Squibbits history only | 10 open or running | phase 2since Jun 26, 2002 | Jun 26, 2002 | none ahead |
| Merckits history only | 10 open or running | phase 3since Aug 25, 2000 | Aug 25, 2000 | none ahead |
| Skingenixits history only | 11 open or running | phase 2since Feb 14, 2011 | Feb 14, 2011 | Dec 31, 2026phase 2 · NCT01297400 |
| Sun Pharmaceutical Industriesits history only | 11 open or running | phase 1since Jul 22, 2026 | Jul 22, 2026 | Dec 2026phase 1 · NCT07729579 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 25, 2000First study: phase 3 study in Alzheimer DiseaseNew to MerckMerck · NCT00006187 · United States
- May 2, 2002Pfizer’s first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to PfizerPfizer · NCT00034957 · United States
- May 8, 2002Phase 1 study in Multiple MyelomaPfizer · NCT00036140 · United States
- Jun 26, 2002Bristol-Myers Squibb’s first study: phase 2 study in Colorectal NeoplasmsNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT00040391 · United States
- Apr 23, 2009Novartis’s first study: phase 2 study in SeizuresNew to NovartisNovartis · NCT00887861 · 37 enrolled · Germany
- Jun 15, 2010Phase 2 study in Nervous System DiseasesNovartis · NCT01147003 · 93 enrolled · United States, Bulgaria, Germany and more
- Feb 14, 2011Skingenix’s first study: phase 2 study in BurnsNew to SkingenixSkingenix · NCT01297400 · 60 planned · United States, Mexico
- Mar 13, 2024EyeD Pharma’s first study: phase 1 study in Glaucoma, Open-AngleNew to EyeD PharmaEyeD Pharma · NCT06321562 · 1 enrolled · Germany
- Jun 17, 2025Phase 2 study in GlaucomaEyeD Pharma · NCT07036510 · 42 planned · Panama
- Jul 22, 2026Sun Pharmaceutical Industries’ first study: phase 1 study in Keratosis, ActinicNew to Sun Pharmaceutical IndustriesSun Pharmaceutical Industries · NCT07729579 · 48 planned · United States
Ahead
- Dec 2026Primary completion: phase 1 study in Keratosis, ActinicSun Pharmaceutical Industries · NCT07729579
- Dec 31, 2026Primary completion: phase 2 study in BurnsSkingenix · NCT01297400
- Jan 2027Primary completion: phase 2 study in GlaucomaEyeD Pharma · NCT07036510
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07729579Keratosis, Actinic · United States | 1 | Recruiting | Sun Pharmaceutical Industries | Dec 2026 | 48 |
| NCT07036510Glaucoma · Panama | 2 | Recruiting | EyeD Pharma | Jan 2027 | 42 |
| NCT06321562Glaucoma, Open-Angle · Germany | 1 | Terminated | EyeD Pharma | Jun 26, 2025 | 1 |
| NCT01297400Burns · United States, Mexico | 2 | Recruiting | Skingenix | Dec 31, 2026 | 60 |
| NCT01147003Nervous System Diseases · United States, Bulgaria, Germany and more | 2 | Completed | Novartis | Sep 2011 | 93 |
| NCT00887861Seizures · Germany | 2 | Completed | Novartis | Aug 2010 | 37 |
| NCT00040391Colorectal Neoplasms · United States | 2 | Terminated | Bristol-Myers Squibb | ||
| NCT00036140Multiple Myeloma · United States | 1 | Completed | Pfizer | ||
| NCT00034957Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | Pfizer | Oct 2002 | |
| NCT00006187Alzheimer Disease · United States | 3 | Terminated | Merck | Jun 2005 |
How it is read
Names in the registry
- “Investigational drug”, 5 entries
- “Investigational new drug, company code: BGG492”, 3 entries
- “TimoD implant”, 2 entries
- “Investigational Drug, MW-III”, 1 entry
Conditions, from the studies’ own filings
- Keratosis, Actinic, 1 study
- Glaucoma, 1 study
- Burns, 1 study
- Glaucoma, Open-Angle, 1 study
- Nervous System Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.